2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one

• ChemBase ID: 72560
• Molecular Formular: C16H13NO3
• Molecular Mass: 267.27932
• Monoisotopic Mass: 267.08954328
• SMILES: c1ccc2c(c1)c(=O)cc(o2)c1cccc(c1N)OC
• Canonical SMILES: COc1cccc(c1N)c1cc(=O)c2c(o1)cccc2
• InChI: InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3
• InChIKey: QFWCYNPOPKQOKV-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one
• IUPAC Traditional name: 2-(2-amino-3-methoxyphenyl)chromen-4-one
• Synonyms: PD98059; 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; PD98059; PD 98,059; PD 98059; 2'-AMINO-3'-METHOXYFLAVONE

Database IDs

• CAS Number: 167869-21-8
• MDL Number: MFCD00671789
• PubChem SID: 162037485; 24278666
• PubChem CID: 4713

CALCULATED PROPERTIES

• Acid pKa: 15.626329
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): 1.9785058
• LogD (pH = 7.4): 1.980759
• Log P: 1.9807879
• Molar Refractivity: 78.1348 cm^3
• Polarizability: 28.923859 Å^3
• Polar Surface Area: 61.55 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO; DMSO: soluble10 mg/mL, clear
• Apperance: yellow solid

Safety Information

• Storage Condition: -20°C; -20°C, Desiccate, Protect from light
• European Hazard Symbols: Harmful (Xn)
• UN Number: 2811
• German water hazard class: 3
• Hazard Class: 6.1
• Packing Group: 3
• Risk Statements: 22
• GHS Pictograms: GHS06
• GHS Signal Word: Danger
• GHS Hazard statements: H301
• GHS Precautionary statements: P301 + P310
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Faceshields, Gloves
• RID/ADR: UN 2811 6.1/PG 3
• Storage Temperature: -20°C

Pharmacology Properties

• Target: MEK
• Gene Information: human ... MAP2K1(5604), MAP2K2(5605), MAP2K3(5606), MAP2K4(6416), MAP2K5(5607), MAP2K6(5608), MAP2K7(5609), MAP3K1(4214), RAF1(5894)

Product Information

• Purity: >95%
• Salt Data: Free Base

DETAILS

MP Biomedicals - 02195935

Purity: >95%
MAP kinase activation inhibitor. Inhibits cell growth and reverses the phenotype of ras -transformed BalB 3T3 fibroblasts.

Selleck Chemicals - S1177

Research Area

• Description: Cancer

Biological Activity

• Description: PD98059 is a non-competitive MEK inhibitor with IC50 of 2 μM.
• Targets: MEK1
• IC50: 2 μM ^[1]
• In Vitro: PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. ^[1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. ^[2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. ^[3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. ^[6]
• In Vivo: Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. ^[4] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. ^[7] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. ^[11]
• Features: Not inhibits c-Raf phosphorylated MEK1

Combination Therapy

• Description: PD98059 pre-treatment sensitizes the human melanoma cell line C8161 to Cisplatin-induced apoptosis. Concomitant addition of PD98059 and Cisplatin does not have any sensitizing effect. ^[5] In androgen-independent C-81 LNCaP cells, PD98059, but not U0126, plus Docetaxel results in enhanced growth suppression by an additional 20% compared to the sum of each agent alone, and enhances docetaxel-induced apoptosis. ^[8] PD98059 in combination with LY294002 synergistically induces apoptosis of human leukemic U937 cells. ^[9] PD98059 acts synergistically with Nutlin-3A to induce apoptosis in wild-type p53 AML cell lines OCI-AML-3 and MOLM-13. ^[10]

Protocol

• Protocol: Kinase Assay ^[1]
• In vitro MEK-inhibitory activity: Incorporation of ^32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-^32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
• Protocol: Cell Assay ^[1]
• Cell Lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
• Concentrations: Dissolved in DMSO, final concentrations ~100 μM
• Incubation Time: 3 dyas, or 7-10 days
• Methods: For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.
• Protocol: Animal Study ^[7]
• Animal Models: Male Sprague–Dawley rats with acute pancreatitis
• Formulation: Dissolved in DMSO, and diluted in saline
• Doses: 10 mg/kg
• Administration: Injection i.v.

References

• References: [1] Dudley DT, et al. Proc Natl Acad Sci U S A, 1995, 92(17), 7686-7689.
• References: [2] Alessi DR, et al. J Biol Chem, 1995, 270(46), 27489-27494.
• References: [3] Pang L, et al. J Biol Chem, 1995, 270(23), 13585-13588.
• References: [4] Alessandrini A, et al. Proc Natl Acad Sci U S A, 1999, 96(22), 12866-12869.
• References: [5] Mandic A, et al. Melanoma Res, 2001, 11(1), 11-19.
• References: [6] Hotokezaka H, et al. J Biol Chem, 2002, 277(49), 47366-47372.
• References: [7] Clemons AP, et al. Pancreas, 2002, 25(3), 251-259.
• References: [8] Zelivianski S, et al. Int J Cancer, 2003, 107(3), 478-485.
• References: [9] Moon DO, et al. Int Immunopharmacol, 2007, 7(1), 36-45.
• References: [10] Kojima K, et al. Cancer Res, 2007, 67(7), 3210-3219.

Sigma Aldrich - P215

Biochem/physiol Actions
Specific inhibitor of the activation of mitogen-activated protein kinase kinase (MAPKK).
Legal Information
Sold with permission of Warner Lambert Company.

REFERENCES

• Dudley DT, et al. Proc Natl Acad Sci U S A, 1995, 92(17), 7686-7689.
• Alessi DR, et al. J Biol Chem, 1995, 270(46), 27489-27494.
• Pang L, et al. J Biol Chem, 1995, 270(23), 13585-13588.
• Clemons AP, et al. Pancreas, 2002, 25(3), 251-259.
• Zelivianski S, et al. Int J Cancer, 2003, 107(3), 478-485.
• Moon DO, et al. Int Immunopharmacol, 2007, 7(1), 36-45.
• Kojima K, et al. Cancer Res, 2007, 67(7), 3210-3219.
• Alessandrini A, et al. Proc Natl Acad Sci U S A, 1999, 96(22), 12866-12869.
• Mandic A, et al. Melanoma Res, 2001, 11(1), 11-19.
• Hotokezaka H, et al. J Biol Chem, 2002, 277(49), 47366-47372.